TY - JOUR
T1 - Traitement des cancers bronchopulmonaires non à petites cellules métastatiques
T2 - Quelle chimiothérapie?
AU - Berhoune, M.
AU - Maestroni, M. L.
AU - Scotte, F.
AU - Prognon, P.
AU - Bonan, B.
PY - 2007/1/1
Y1 - 2007/1/1
N2 - The therapeutic strategy of metastatic non-small-cell lung cancer (NSCLC) has known a qualitative evolution these last ten years. The added value of chemotherapy versus palliative care has been demonstrated by several meta-analyses. New molecules with better efficacy-toxicity ratio (vinorelbine, paclitaxel, docetaxel, gemcitabine, pemetrexed) improved the therapeutic strategy according to the patient performance status. Platinum-based combination remains the standard of care in first line treatment with a median survival of 8 months and a one-year median survival of 35%, while no particular doublet shown its superiority. Currently, a second line treatment is a standard. Regarding targeted therapies, their role in NSCLC are under way.
AB - The therapeutic strategy of metastatic non-small-cell lung cancer (NSCLC) has known a qualitative evolution these last ten years. The added value of chemotherapy versus palliative care has been demonstrated by several meta-analyses. New molecules with better efficacy-toxicity ratio (vinorelbine, paclitaxel, docetaxel, gemcitabine, pemetrexed) improved the therapeutic strategy according to the patient performance status. Platinum-based combination remains the standard of care in first line treatment with a median survival of 8 months and a one-year median survival of 35%, while no particular doublet shown its superiority. Currently, a second line treatment is a standard. Regarding targeted therapies, their role in NSCLC are under way.
KW - Chemotherapy
KW - Non-small-cell lung cancer
KW - Palliative care
KW - Quality of life
KW - Targeted therapies
KW - Therapeutic strategy
UR - http://www.scopus.com/inward/record.url?scp=34147207747&partnerID=8YFLogxK
U2 - 10.1684/jpc.2007.0034
DO - 10.1684/jpc.2007.0034
M3 - Article
AN - SCOPUS:34147207747
SN - 0291-1981
VL - 26
SP - 15
EP - 24
JO - Journal de Pharmacie Clinique
JF - Journal de Pharmacie Clinique
IS - 1
ER -